

Zobair M Younossi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2066308/zobair-m-younossi-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

582
papers

55,004
citations

98
h-index

226
g-index

624
ext. papers

69,407
ext. citations

5.9
avg, IF

8.26
L-index

#	Paper	IF	Citations
582	Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	1
581	Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease.. <i>American Journal of Gastroenterology</i> , 2022 , 117,	0.7	2
580	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.. <i>Journal of Hepatology</i> , 2022 ,	13.4	5
579	Response to: Chronic Liver Disease Among Adolescent and Young Adult: Alcohol Use Disorder Identification- Letter to the Editor. <i>Hepatology</i> 2022.. <i>Hepatology</i> , 2022 ,	11.2	
578	Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system.. <i>PLoS ONE</i> , 2022 , 17, e0263417	3.7	0
577	Interrelationship between physical activity and depression in nonalcoholic fatty liver disease.. <i>World Journal of Hepatology</i> , 2022 , 14, 612-622	3.4	0
576	Health-Related Quality of Life and Health Care Resource Utilization in Patients With Chronic Liver Disease and Primary Liver Cancer in the United States: Analysis of Medical Expenditure Panel Survey.. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 , 12, 272-277	4.1	
575	Are There Outcomes Differences Between Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Associated Fatty Liver Disease (MAFLD)?. <i>Hepatology</i> , 2022 ,	11.2	7
574	Service line care delivery model for COVID-19 patient-centric care.. <i>American Journal of Managed Care</i> , 2022 , 28, e80-e87	2.1	
573	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).. <i>Endocrine Practice</i> , 2022 , 28, 528-562	3.2	16
572	Response to Letters to the Editors.. <i>Hepatology</i> , 2022 ,	11.2	
571	Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH).. <i>Endocrine Practice</i> , 2021 ,	3.2	2
570	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021 , 116, 254-262	0.7	20
569	Global Burden of Non-alcoholic Fatty Liver Disease (NAFLD) and chronic liver disease (CLD) Among Adolescents and Young Adults. <i>Hepatology</i> , 2021 ,	11.2	4
568	Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. <i>Annals of Hepatology</i> , 2021 , 27, 100556	3.1	1
567	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
566	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021 ,	13.3	5

565	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4
564	The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
563	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
562	Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021 ,	11.2	7
561	Recent Trends in the Global Burden of Hepatitis B Virus: 2007-2017. <i>Gastroenterology</i> , 2021 , 160, 1845-1854	14.6	34
560	Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00340	4.2	5
559	Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States. <i>JHEP Reports</i> , 2021 , 3, 100236	10.3	0
558	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021 , 5, 1201-1211	6	4
557	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021 , 74, 133-147	11.2	20
556	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100280	10.3	0
555	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1299-1300	6.9	2
554	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 717-729	24.2	16
553	Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	16
552	Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
551	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	9
550	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
549	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021 , 44, 2162-2172	14.6	5
548	From NAFLD to MAFLD: Implications of a Premature Change in Terminology. <i>Hepatology</i> , 2021 , 73, 1194-1198	11.98	111

547	Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 580-589.e5	6.9	74
546	Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 629-636	4	7
545	Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1240-1247.e5	6.9	14
544	Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience. <i>Annals of Hepatology</i> , 2021 , 22, 100277	3.1	5
543	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021 , 160, 1608-1619.e13	13.3	15
542	Integrating Patient-Reported Outcomes Within Routine Hepatology Care: A Prompt to Action. <i>Hepatology</i> , 2021 , 73, 1570-1580	11.2	3
541	AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. <i>Gastroenterology</i> , 2021 , 160, 912-918	13.3	62
540	Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 484-492	3.4	1
539	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021 , 73, 2028-2038	11.2	31
538	Major Histocompatibility Complex Class I-Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2021 , 5, 63-73	6	2
537	Patient-Reported Outcomes in Hepatitis C Infection 2021 , 213-219		
536	Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2021 , 31, 2002-2010	3.7	5
535	Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. <i>Hepatology Communications</i> , 2021 , 5, 1676-1688	6	6
534	Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. <i>Hepatology Communications</i> , 2021 , 5, 1833-1847	6	7
533	The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S3-S13	13.4	7
532	The impact of hepatocellular carcinoma diagnosis on patients' health-related quality of life. <i>Cancer Medicine</i> , 2021 , 10, 6273-6281	4.8	3
531	Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. <i>Hepatology Communications</i> , 2021 ,	6	5
530	Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis. <i>Life</i> , 2021 , 11,	3	1

529	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>JHEP Reports</i> , 2021 , 3, 100305	10.3	13
528	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021 , 29, 1401-1412	8	1
527	Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1239-1248	1.9	1
526	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021 , 161, 1030-1042.e8	13.3	7
525	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021 , 122, 1548227	22.7	4
524	Nonalcoholic steatohepatitis: global impact and clinical consequences. <i>Endocrine Connections</i> , 2021 , 10, R240-R247	3.5	3
523	Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2021 , 4, e2123923	10.4	3
522	Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. <i>Journal of Hepatology</i> , 2021 , 75, 795-809	13.4	16
521	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
520	The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. <i>Hepatology Communications</i> , 2021 , 5, 749-759	6	4
519	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
518	Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD.. <i>Hepatology Communications</i> , 2021 ,	6	2
517	Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease (NAFLD) among Adults in the United States (U.S.), 1999-2016.. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
516	Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes. <i>Clinical Infectious Diseases</i> , 2020 , 70, 628-632	11.6	5
515	The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. <i>Hepatology Communications</i> , 2020 , 4, 1769-1780	6	17
514	Decline in Annual Mortality of Hepatitis C Virus-Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. <i>Gastroenterology</i> , 2020 , 159, 1558-1560.e2	13.3	4
513	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020 , 50, 1024-1031	5.1	13
512	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020 , 73, 26-39	13.4	137

511	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 513-526	6.1	23
510	Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. <i>Hepatology</i> , 2020 , 72, 1605-1616	11.2	129
509	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
508	Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. <i>Diabetes Care</i> , 2020 , 43, 283-289	14.6	58
507	Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006-2016. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz509	1	7
506	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020 , 158, 1611-1625.e12	13.3	234
505	Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States. <i>Hepatology Communications</i> , 2020 , 4, 890-903	6	20
504	Epidemiology of Non-alcoholic Fatty Liver Disease in North America. <i>Current Pharmaceutical Design</i> , 2020 , 26, 993-997	3.3	11
503	Management of nonalcoholic fatty liver disease in the Middle East. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3528-3541	5.6	7
502	Outcomes of liver transplantation by insurance types in the United States. <i>American Journal of Managed Care</i> , 2020 , 26, e121-e126	2.1	7
501	Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2020 , 2, 100171	10.3	21
500	Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. <i>Liver International</i> , 2020 , 40, 308-318	7.9	2
499	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020 , 89, 105922	2.3	49
498	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020 , 40, 260-270	7.9	14
497	The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 291-304	6.1	18
496	Increased cancer rates in patients with chronic hepatitis C. <i>Liver International</i> , 2020 , 40, 685-693	7.9	10
495	Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. <i>Journal of Clinical Gastroenterology</i> , 2020 , 54, 459-467	3	28
494	The Burden of NAFLD Worldwide 2020 , 15-24		

493	Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. <i>Hepatology Communications</i> , 2020 , 4, 1136-1148	6	21
492	Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1496-1504	0.7	8
491	Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 1915-1923	2.3	1
490	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020 , 4, 1637-1650	6	12
489	Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. <i>Journal of Gastroenterology</i> , 2020 , 55, 330-341	6.9	13
488	Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 468-476.e11	6.9	10
487	Epidemiology of chronic liver diseases in the USA in the past three decades. <i>Gut</i> , 2020 , 69, 564-568	19.2	136
486	Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 416-422	4	3
485	Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. <i>Hepatology International</i> , 2020 , 14, 556-566	8.8	9
484	Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes. <i>Scientific Reports</i> , 2020 , 10, 6800	4.9	5
483	Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1761	6.1	1
482	Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study. <i>Journal of Neuroimmunology</i> , 2019 , 335, 577022	3.5	5
481	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2383-2384	6.9	1
480	A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. <i>Hematology</i> , 2019 , 24, 679-719	2.2	10
479	Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States. <i>Hepatology Communications</i> , 2019 , 3, 356-364	6	4
478	Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. <i>Hepatology International</i> , 2019 , 13, 205-213	8.8	29
477	Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , 2019 , 39, 1837-1844	7.9	8
476	Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019 , 3, 1050-1060	6	23

475	Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. <i>Liver International</i> , 2019 , 39, 1661-1671	7.9	17
474	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. <i>BMC Gastroenterology</i> , 2019 , 19, 56	3	31
473	Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2093-2100.e3	6.9	18
472	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2552-2560.e10	6.9	33
471	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019 , 70, 1913-1927	11.2	111
470	Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, e341-e347	3	
469	Disease Burden of Hepatocellular Carcinoma: A Global Perspective. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 910-917	4	128
468	Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. <i>Liver International</i> , 2019 , 39, 1631-1640	7.9	7
467	Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. <i>Clinical Diabetes</i> , 2019 , 37, 65-72	2.9	40
466	Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C. <i>Liver International</i> , 2019 , 39, 54-59	7.9	20
465	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 748-755.e3	6.9	311
464	Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019 , 25, 68-78	4.5	12
463	Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. <i>Hepatology</i> , 2019 , 69, 237-244	11.2	13
462	Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2019 , 69, 1064-1074	11.2	97
461	Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1293-1300	3.4	3
460	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019 , 84, 105803	2.3	72
459	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019 , 70, 1521-1530	11.2	113
458	The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019 , 71, 793-801	13.4	518

457	Hepatocellular carcinoma and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019 , 13, 688-694		31
456	Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. <i>Hepatology Communications</i> , 2019 , 3, 1459-1471	6	65
455	Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. <i>Journal of Sports Medicine and Physical Fitness</i> , 2019 , 59, 1376-1388	1.4	10
454	Importance of fatigue and its measurement in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2019 , 25, 3669-3683	5.6	17
453	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1625-1633.e1	6.9	56
452	Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2019 , 19, 27	3	11
451	Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 644-653	6.1	16
450	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1636-1641	0.7	16
449	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40	425
448	Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2019 , 98, e16704	1.8	4
447	A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 331-341	3	21
446	Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 262-268	3	2
445	Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. <i>Hepatology</i> , 2019 , 69, 564-572	11.2	69
444	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019 , 69, 2672-2682	11.2	557
443	Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 693-698	3	4
442	Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1641-1642.e1	6.9	7
441	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 22-27	1.8	181
440	Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. <i>Liver International</i> , 2019 , 39, 748-757	7.9	23

439	Non-alcoholic fatty liver disease - A global public health perspective. <i>Journal of Hepatology</i> , 2019 , 70, 531-544	13.4	685
438	Diagnosis and Management of Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 48-63	0.7	41
437	Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population. <i>Hepatology Communications</i> , 2019 , 3, 74-83	6	14
436	Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019 , 39, 342-352	7.9	23
435	Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. <i>Liver International</i> , 2019 , 39, 332-341	7.9	27
434	Nonalcoholic Fatty Liver is Contributing to the Increase in Cases of Liver Disease in US Emergency Departments. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 58-64	3	3
433	Impact of hepatitis C virus and insurance coverage on mortality. <i>American Journal of Managed Care</i> , 2019 , 25, 61-67	2.1	2
432	French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. <i>Value in Health</i> , 2018 , 21, 1218-1225	3.3	16
431	Patients with refractory ascites treated with alfapump [®] system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. <i>Quality of Life Research</i> , 2018 , 27, 1513-1520	3.7	22
430	Quality of Life in Patients with Cirrhosis—Measurement and Clinical Impact. <i>Current Hepatology Reports</i> , 2018 , 17, 15-21	1	1
429	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 811-817	3.4	19
428	Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1511-1522	6.1	23
427	The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD). <i>Current Gastroenterology Reports</i> , 2018 , 20, 24	5	3
426	Patient-Reported Outcomes for Patients With Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 793-799	6.9	10
425	Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). <i>BMJ Open Gastroenterology</i> , 2018 , 5, e000198	3.9	20
424	Reply. <i>Hepatology</i> , 2018 , 68, 390	11.2	
423	Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 965-973.e2	6.9	19
422	Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. <i>Liver International</i> , 2018 , 38, 1849-1859	7.9	47

421	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. <i>Liver Transplantation</i> , 2018 , 24, 166-170	4.5	34
420	Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 567-574.e6	6.9	22
419	Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 680-688	6.1	9
418	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1742-1750	11.6	20
417	Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. <i>Journal of Infectious Diseases</i> , 2018 , 217, 1033-1043	7	19
416	The epidemiology of nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018 , 11, 92-94	2.2	36
415	Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1641-1649.e6	6.9	16
414	Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). <i>Medicine (United States)</i> , 2018 , 97, e0214	1.8	86
413	Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 945-951	3.4	16
412	In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. <i>Liver International</i> , 2018 , 38, 258-265	7.9	29
411	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018 , 67, 328-357	11.2	2641
410	Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 123-128	6.1	11
409	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 228-235	3.4	9
408	Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 452-453	6.9	28
407	Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018 , 22, 1-10	4.6	56
406	Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018 , 66, 112-116	2.8	21
405	Reply. <i>Hepatology</i> , 2018 , 67, 450-451	11.2	
404	Waist-to-calf circumference ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1082-1091	4	11

403	The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. <i>Hepatology</i> , 2018 , 67, 1160-1162	11.2	2
402	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 11-20	24.2	1902
401	Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH). <i>PLoS ONE</i> , 2018 , 13, e0199294	3.7	10
400	Response to the letter: Hepatitis C screening in opioid epidemics in the United States and societal perspectives. <i>Liver International</i> , 2018 , 38, 1331	7.9	
399	Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. <i>Hepatology</i> , 2018 , 68, 2405-2412	11.2	25
398	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1429-1437	3.4	14
397	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1608-1616	3.4	3
396	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018 , 69, 1365-1370	13.4	29
395	Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus. <i>Psychosomatics</i> , 2018 , 59, 567-574	2.6	18
394	Chronic kidney disease in patients with chronic hepatitis C virus infection. <i>Minerva Gastroenterologica E Dietologica</i> , 2018 , 64, 376-382	1.6	1
393	Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). <i>Value in Health</i> , 2018 , 21, 612-621	3.3	5
392	Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 259-267	6.1	30
391	Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 354-362	3.4	15
390	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018 , 38, 1179-1187	7.9	16
389	Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. <i>Hepatology</i> , 2018 , 68, 155-165	11.2	14
388	Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. <i>Hepatology</i> , 2018 , 67, 123-133	11.2	787
387	Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. <i>Annals of Hepatology</i> , 2018 , 17, 11-13	3.1	3
386	Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. <i>Medicine (United States)</i> , 2018 , 97, e11518	1.8	33

385	Exercise as an intervention for patients with end-stage liver disease: Systematic review. <i>Medicine (United States)</i> , 2018 , 97, e12774	1.8	7
384	A176 SOFOSBUVIR/VELPATASVIR-BASED REGIMENS ARE ASSOCIATED WITH EXCELLENT EFFICACY AND A SIGNIFICANT IMPROVEMENT OF PATIENTS-REPORTED OUTCOMES ACROSS PATIENT POPULATIONS: FROM NON-CIRRHOTICS TO COMPENSATED CIRRHOTICS TO DECOMPENSATED CIRRHOTICS. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 307-308	0.5	78
383	Association of Parity in Patients with Chronic Liver Disease. <i>Annals of Hepatology</i> , 2018 , 17, 1035-1041	3.1	2
382	Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818811508	4.7	12
381	Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes. <i>Current Hepatology Reports</i> , 2018 , 17, 459-465	1	
380	The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. <i>Journal of Viral Hepatitis</i> , 2018 , 25 Suppl 3, 6-14	3.4	21
379	Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. <i>Hepatology Communications</i> , 2018 , 2, 1227-1234	6	8
378	Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. <i>PLoS ONE</i> , 2018 , 13, e0204772	3.7	15
377	The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. <i>Current Hepatology Reports</i> , 2018 , 17, 345-349	1	3
376	An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018 , 16, 170	11.4	5
375	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018 , 155, 1140-1153	13.3	156
374	The impact of sustained virologic response on severe fatigue in patients with chronic hepatitis C: The role of HCV viremia and co-morbidities. <i>Journal of Hepatology</i> , 2018 , 68, S531	13.4	3
373	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis 2018 , 68, 349		1
372	Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 313-315	6.9	10
371	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017 , 65, 1557-1565	11.2	796
370	The epidemiologic characteristics, temporal trends, predictors of death, and discharge disposition in patients with a diagnosis of sepsis: A cross-sectional retrospective cohort study. <i>Journal of Critical Care</i> , 2017 , 39, 48-55	4	10
369	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017 , 66, 1282-1299	13.4	58
368	A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. <i>Liver International</i> , 2017 , 37, 1209-1218	7.9	47

367	Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 789-796	3.4	12
366	Hepatitis C virus infection. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17006	51.1	224
365	Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. <i>Health and Quality of Life Outcomes</i> , 2017 , 15, 25	3	18
364	Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. <i>Hepatology</i> , 2017 , 66, 46-56	11.2	23
363	Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1087-1094.e2	6.9	12
362	Hepatitis C Infection: A Systemic Disease. <i>Clinics in Liver Disease</i> , 2017 , 21, 449-453	4.6	21
361	Economic Burden of Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017 , 21, 579-594	4.6	42
360	Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. <i>Liver International</i> , 2017 , 37, 1796-1804	7.9	28
359	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2174-2181	4	18
358	Patient-Reported Outcomes and Fatigue in Patients with Chronic Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017 , 21, 565-578	4.6	27
357	Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. <i>Gastroenterology</i> , 2017 , 152, 1588-1598	13.3	7
356	The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017 , 37, 662-668	7.9	16
355	Dermatologic Manifestations of Chronic Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017 , 21, 555-564	4.6	21
354	Alfapump [®] system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. <i>Journal of Hepatology</i> , 2017 , 67, 940-949	13.4	56
353	Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1144-1147	6.9	16
352	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017 , 10, 605-614	3.7	4
351	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017 , 16, 523-541	13.6	66
350	Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1700-1708	0.7	15

349	Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2017 , 16, 555-564	3.1	15
348	The Prevalence of Parkinson Disease Among Patients With Hepatitis C Infection. <i>Annals of Hepatology</i> , 2017 , 16, 342-348	3.1	7
347	Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 2695-2706	4.4	16
346	Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 540-548	6.1	29
345	Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2915-2922	4	141
344	Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2017 , 21, 739-753	4.6	25
343	Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017 , 1, 421-428	6	72
342	Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. <i>Medicine (United States)</i> , 2017 , 96, e5904	1.8	106
341	Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity. <i>Medicine (United States)</i> , 2017 , 96, e5914	1.8	38
340	Demonstration of two types of fatigue in subjects with chronic liver disease using factor analysis. <i>Quality of Life Research</i> , 2017 , 26, 1777-1784	3.7	6
339	Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 22-27	3.4	62
338	The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017 , 37, 159-172.	2.9	31
337	Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 759-766.e5	6.9	76
336	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 421-430.e6	6.9	62
335	Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. <i>Clinical Diabetes</i> , 2017 , 35, 79-83	2.9	7
334	Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2017 , 51, 254-260	3	53
333	Fatigue and Hepatitis C: a focus group study. <i>Qualitative Research in Medicine & Healthcare</i> , 2017 , 1,	1	2
332	Pediatric Non-Alcoholic Fatty Liver Disease. <i>Children</i> , 2017 , 4,	2.8	27

331	Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017 , 5, 16-22	5.2	3
330	Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017 , 5, 193-196	5.2	5
329	Treating Medicaid patients with hepatitis C: clinical and economic impact. <i>American Journal of Managed Care</i> , 2017 , 23, 107-112	2.1	12
328	Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. <i>Journal of Hepatology</i> , 2016 , 64, 29-36	13.4	26
327	Perception of Effort During Activity in Patients With Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. <i>PM and R</i> , 2016 , 8, 28-34	2.2	7
326	Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. <i>Value in Health</i> , 2016 , 19, 544-51	3.3	31
325	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. <i>Hepatology</i> , 2016 , 64, 1893-1899	11.2	52
324	The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. <i>Hepatology</i> , 2016 , 64, 1577-1586	11.2	569
323	Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. <i>Journal of Hepatology</i> , 2016 , 65, S109-S119	13.4	43
322	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016 , 15, 1145-1160	13.6	69
321	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1042-1048	11.6	45
320	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016 , 22, 1356-66	4.5	19
319	Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry. <i>Clinical Transplantation</i> , 2016 , 30, 1570-1577	3.8	17
318	Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. <i>BMJ Open Gastroenterology</i> , 2016 , 3, e000096	3.9	34
317	Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016 , 3, e000106	3.9	39
316	Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. <i>BMC Gastroenterology</i> , 2016 , 16, 137	3	21
315	The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). <i>Medicine (United States)</i> , 2016 , 95, e5066	1.8	7
314	Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. <i>Medicine (United States)</i> , 2016 , 95, e4151	1.8	56

313	Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. <i>Medicine (United States)</i> , 2016 , 95, e4243	1.8	13
312	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. <i>Medicine (United States)</i> , 2016 , 95, e5048	1.8	29
311	Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016 , 64, 73-84	11.2	4273
310	Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1060-8	6.1	12
309	FATIGUE IN JAPANESE PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH LEDIPASVIR AND SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN. <i>Value in Health</i> , 2016 , 19, A316-A317	3.3	3
308	Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. <i>BMC Gastroenterology</i> , 2016 , 16, 45	3	17
307	Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). <i>Health and Quality of Life Outcomes</i> , 2016 , 14, 18	3	68
306	Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. <i>Health and Quality of Life Outcomes</i> , 2016 , 14, 49	3	2
305	Global Epidemiology and Risk Factors for Nonalcoholic Fatty Liver Disease 2016 , 21-40		1
304	Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. <i>Psychosomatics</i> , 2016 , 57, 82-8	2.6	20
303	Epidemiology and natural history of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 1017-25	12.7	233
302	Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. <i>Gastroenterology</i> , 2016 , 150, 1778-85	13.3	173
301	Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. <i>Gastroenterology</i> , 2016 , 150, 1599-1608	13.3	231
300	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , 2016 , 65, 33-39	13.4	86
299	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. <i>Clinics in Liver Disease</i> , 2016 , 20, 205-14	4.6	311
298	Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 156-64.e3	6.9	47
297	Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 63-71	4.2	37
296	Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher. <i>Journal of Clinical and Translational Hepatology</i> , 2016 , 4, 169-174	5.2	4

295	Treatment strategies for chronic hepatitis C prior to and following liver transplantation. <i>World Journal of Hepatology</i> , 2016 , 8, 69-73	3.4	10
294	Trends in Liver Transplantation in Hepatitis C Virus-Infected Persons, United States. <i>Emerging Infectious Diseases</i> , 2016 , 22, 565-7	10.2	2
293	Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6318-27	5.6	82
292	Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. <i>Medicine (United States)</i> , 2016 , 95, e2482	1.8	10
291	Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens. <i>Journal of the American Geriatrics Society</i> , 2016 , 64, 386-93	5.6	34
290	Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 857-865	3.4	41
289	The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. <i>Liver International</i> , 2016 , 36, 42-8	7.9	43
288	Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 217-26	3.4	40
287	Vaccination against hepatitis A and B in patients with chronic liver disease and type 2 diabetes: has anything changed?. <i>Liver International</i> , 2016 , 36, 1096-100	7.9	8
286	Reply. <i>Hepatology</i> , 2016 , 64, 1391-3	11.2	1
285	Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 271-8	6.1	19
284	Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 447-54	3.4	39
283	Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 623-30	3.4	31
282	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. <i>Medicine (United States)</i> , 2016 , 95, e2702	1.8	31
281	Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naïve patients. <i>Liver International</i> , 2016 , 36, 189-97	7.9	20
280	An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. <i>American Journal of Gastroenterology</i> , 2016 , 111, 808-16	0.7	75
279	Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Current Hepatology Reports</i> , 2016 , 15, 113-116	1	1
278	Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 2505-15	4	9

277	Letter: effects of hepatitis C infection on the post-lung transplant mortality - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 768-9	6.1	
276	The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). <i>BMC Medical Genetics</i> , 2016 , 17, 63	2.1	20
275	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 122-132	18.8	52
274	Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 659-665	2.2	6
273	The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 53-61	3.4	8
272	Letter: new treatments for hepatitis C have implications for quality of life in people who inject drug--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 841-2	6.1	1
271	Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. <i>American Journal of Managed Care</i> , 2016 , 22, SP205-11	2.1	29
270	Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015 , 212, 367-77	7	46
269	Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. <i>Pharmacoeconomics</i> , 2015 , 33, 1245-53	4.4	57
268	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. <i>Therapeutic Advances in Gastroenterology</i> , 2015 , 8, 298-312	4.7	83
267	Resource utilization and survival among Medicare patients with advanced liver disease. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 320-32	4	9
266	A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Hepatology</i> , 2015 , 62, 1204-6	13.4	49
265	Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3248-51	4	23
264	Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. <i>Journal of Hepatology</i> , 2015 , 63, 337-45	13.4	116
263	Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 222-7	3	38
262	Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 137-45	3.4	23
261	Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 900-8	4	4
260	The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17000 HCV-infected transplant recipients. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 209-17	6.1	14

259	Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study. <i>Annals of Medicine</i> , 2015 , 47, 40-6	1.5	29
258	Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. <i>Liver International</i> , 2015 , 35, 1367-72	7.9	20
257	Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 8-17	3.4	13
256	Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". <i>Journal of Hepatology</i> , 2015 , 63, 1534-5	13.4	1
255	Overall health-related quality of life in patients with end-stage liver disease. <i>Clinical Liver Disease</i> , 2015 , 6, 9-14	2.2	20
254	The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?. <i>Clinical Liver Disease</i> , 2015 , 6, 126-128	2.2	3
253	Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 497-520	6.1	130
252	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2015 , 15, 175	3	22
251	Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. <i>Hepatology</i> , 2015 , 62, 1723-30	11.2	460
250	The outcomes of adult liver transplants in the United States from 1987 to 2013. <i>Liver International</i> , 2015 , 35, 2036-41	7.9	21
249	A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 897-905	3.4	61
248	Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 977-82	3.4	14
247	The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 286-95	6.1	74
246	HCV infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States. <i>Clinical Transplantation</i> , 2015 , 29, 920-6	3.8	6
245	Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. <i>Hepatology</i> , 2015 , 61, 1471-8	11.2	42
244	Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1317-26	4.1	16
243	What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?. <i>Clinical Liver Disease</i> , 2015 , 6, 117-119	2.2	7
242	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 544-63	6.1	96

241	Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. <i>Hepatology</i> , 2015 , 61, 1798-808	11.2	109
240	Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. <i>Gastroenterology</i> , 2015 , 148, 547-55	13.3	1135
239	Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. <i>Liver International</i> , 2015 , 35, 448-54	7.9	6
238	Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1349-59.e13	6.9	72
237	Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). <i>Journal of Hepatology</i> , 2014 , 60, 741-7	13.4	82
236	Obesity-associated nonalcoholic fatty liver disease. <i>Clinics in Liver Disease</i> , 2014 , 18, 19-31	4.6	59
235	Adipokines in Nonalcoholic Fatty Liver Disease 2014 , 249-283		1
234	Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. <i>Journal of Hepatology</i> , 2014 , 60, 530-7	13.4	98
233	The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46 Suppl 5, S186-96	3.3	53
232	The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 686-94	6.1	55
231	Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 676-85	6.1	29
230	The impact of hepatitis C burden: an evidence-based approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 518-31	6.1	97
229	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 657-75	6.1	52
228	Hepatitis. Chronic HCV infection, diabetes and liver-related outcomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 520-1	24.2	5
227	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. <i>Lancet, The</i> , 2014 , 384, 1756-65	4.0	662
226	Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 1586-93	4	47
225	Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2014 , 14, 72	3	5
224	Host genetic variants in obesity-related nonalcoholic fatty liver disease. <i>Clinics in Liver Disease</i> , 2014 , 18, 249-67	4.6	7

223	Adipose tissue as an endocrine organ. <i>Clinics in Liver Disease</i> , 2014 , 18, 41-58	4.6	112
222	Sofosbuvir (Sovaldi) for the treatment of hepatitis C. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 555-66	3.8	18
221	Inpatient economic and mortality assessment for liver transplantation: a nationwide study of the United States data from 2005 to 2009. <i>Transplantation</i> , 2014 , 97, 98-103	1.8	17
220	Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. <i>Annals of Hepatology</i> , 2014 , 13, 60-64	3.1	6
219	Survey of health status, nutrition and geography of food selection of chronic liver disease patients. <i>Annals of Hepatology</i> , 2014 , 13, 533-540	3.1	15
218	Statin use is not associated with liver related mortality. <i>Annals of Hepatology</i> , 2014 , 13, 84-90	3.1	8
217	Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. <i>BMC Gastroenterology</i> , 2014 , 14, 208	3	17
216	Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. <i>BMJ Open</i> , 2014 , 4, e004318	3	27
215	Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 2006-13	4	35
214	Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1528-34	4	12
213	Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. <i>Hepatology</i> , 2014 , 59, 2161-9	11.2	69
212	Multiple factors predict physical performance in people with chronic liver disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2014 , 93, 470-6	2.6	18
211	The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. <i>JAMA Internal Medicine</i> , 2014 , 174, 1407-9	11.5	30
210	Obesity and liver disease. <i>Clinics in Liver Disease</i> , 2014 , 18, xiii-xiv	4.6	1
209	Reply to: "Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right". <i>Journal of Hepatology</i> , 2014 , 61, 454-5	13.4	
208	Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. <i>Journal of Hepatology</i> , 2014 , 61, 228-34	13.4	80
207	Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 3-14	6.1	66
206	Survey of health status, nutrition and geography of food selection of chronic liver disease patients. <i>Annals of Hepatology</i> , 2014 , 13, 533-40	3.1	9

205	Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). <i>Journal of Translational Medicine</i> , 2013 , 11, 133	8.5	46
204	Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3017-23	4	177
203	Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2013 , 3, 181-5	4.1	26
202	Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 124-33	6.1	37
201	Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013 , 58, 488-94	13.4	17
200	Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1410-5	4	31
199	Comparison of activity level among patients with chronic liver disease. <i>Disability and Rehabilitation</i> , 2013 , 35, 907-12	2.4	10
198	The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1065-75	6.1	28
197	Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 557-8	6.1	1
196	Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 703-9	6.1	51
195	In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 352-60	12.7	112
194	Associations of chronic hepatitis C with metabolic and cardiac outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 647-52	6.1	114
193	Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 1132-40	4	43
192	Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013 , 58, 883-9	13.4	46
191	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013 , 58, 1897-906	11.2	19
190	Sofosbuvir for previously untreated chronic hepatitis C infection. <i>New England Journal of Medicine</i> , 2013 , 368, 1878-87	59.2	1380
189	Quality of life in cirrhosis. <i>Current Gastroenterology Reports</i> , 2013 , 15, 301	5	54
188	Association of chronic liver disease with depression: a population-based study. <i>Psychosomatics</i> , 2013 , 54, 52-9	2.6	53

187	Interaction of type 2 diabetes and nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013 , 7, 405-7	4.2	8
186	Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD. <i>Mediators of Inflammation</i> , 2013 , 2013, 684237	4.3	5
185	Commentary: phlebotomy in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 1112	6.1	2
184	Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 550-5	3.4	31
183	The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. <i>Liver International</i> , 2013 , 33, 1281-6	7.9	25
182	Mortality associated with alcohol-related liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 596-602	6.1	16
181	Current management of patients with nonalcoholic fatty liver disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2013 , 8, 549-558	4.1	1
180	Validation of the chronic liver disease questionnaire in Serbian patients. <i>World Journal of Gastroenterology</i> , 2013 , 19, 4950-7	5.6	11
179	Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example. <i>PLoS ONE</i> , 2013 , 8, e56009	3.7	9
178	Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. <i>Annals of Hepatology</i> , 2013 , 13, 60-4	3.1	2
177	Statin use is not associated with liver related mortality. <i>Annals of Hepatology</i> , 2013 , 13, 84-90	3.1	6
176	Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 341-5	3.4	39
175	Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). <i>Journal of Viral Hepatitis</i> , 2012 , 19, 414-22	3.4	8
174	The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. <i>Journal of Translational Medicine</i> , 2012 , 10, 25	8.5	20
173	Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. <i>Hepatology</i> , 2012 , 55, 968-70	11.2	8
172	Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 772-81	6.1	156
171	The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012 , 142, 1592-609	13.3	1208
170	Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 646-50	6.9	223

169	Natural history of nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2012 , 1, 112-113	2.2	5
168	Commentary: physical activity and NAFLD - cause or effect? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 1098-1099	6.1	0
167	In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1034-41.e1	6.9	167
166	Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2012 , 2, 135-44	4.1	51
165	Disparities in activity level and nutrition between patients with chronic hepatitis C and blood donors. <i>PM and R</i> , 2012 , 4, 436-41	2.2	4
164	The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>American Journal of Gastroenterology</i> , 2012 , 107, 811-26	0.7	279
163	Economic model of a birth cohort screening program for hepatitis C virus. <i>Hepatology</i> , 2012 , 55, 1344-55	11.2	91
162	The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012 , 55, 2005-23	11.2	2285
161	Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). <i>Brain and Behavior</i> , 2012 , 2, 525-31	3.4	12
160	Caffeine is protective in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 76-82	6.1	101
159	The Intestinal Microbiota and Liver Disease. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012 , 1, 9-14		30
158	Nonalcoholic fatty liver disease and bariatric surgery. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 163-71	4.2	25
157	Nonalcoholic fatty liver disease in lean individuals in the United States. <i>Medicine (United States)</i> , 2012 , 91, 319-327	1.8	319
156	African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, e62-5	3	14
155	Validation of CLDQ-HCV as a Health Related Quality of Life (HRQL) Instrument for Patients with Chronic Hepatitis C (CH-C). <i>American Journal of Gastroenterology</i> , 2012 , 107, S159	0.7	2
154	Quality of Life in Hepatic Encephalopathy 2012 , 221-231		1
153	A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. <i>Panminerva Medica</i> , 2012 , 54, 29-37	2	10
152	Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. <i>Clinical Drug Investigation</i> , 2011 , 31, 213-20	3.2	23

151	Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 524-530.e1; quiz e60	6.9	747
150	Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. <i>Psychosomatics</i> , 2011 , 52, 127-32	2.6	91
149	13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY. <i>Journal of Hepatology</i> , 2011 , 54, S6-S7	13.4	49
148	OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study. <i>Gut</i> , 2011 , 60, A55-A55	19.2	
147	Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 801-14	6.1	87
146	Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 274-85	6.1	2020
145	Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 853-61	6.1	98
144	Vietnamese community screening for hepatitis B virus and hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 70-6	3.4	24
143	A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. <i>Obesity Surgery</i> , 2011 , 21, 431-9	3.7	117
142	Biomarkers for Non-invasive Diagnosis of Non-alcoholic Steatohepatitis. <i>Obesity Surgery</i> , 2011 , 21, 1318-1318	3.7	117
141	Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. <i>Obesity Surgery</i> , 2011 , 21, 1750-7	3.7	36
140	Non-invasive markers for hepatic fibrosis. <i>BMC Gastroenterology</i> , 2011 , 11, 91	3	197
139	Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. <i>Hepatology</i> , 2011 , 53, 737-45	11.2	75
138	Reply:. <i>Hepatology</i> , 2011 , 53, 1400-1400	11.2	
137	Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. <i>Hepatology</i> , 2011 , 53, 1874-82	11.2	422
136	Reply:. <i>Hepatology</i> , 2011 , 54, 370-371	11.2	1
135	Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. <i>Hepatology</i> , 2011 , 54, 1167-78	11.2	26
134	Telaprevir for retreatment of HCV infection. <i>New England Journal of Medicine</i> , 2011 , 364, 2417-28	59.2	1279

133	Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). <i>Journal of Proteome Research</i> , 2011 , 10, 774-9	5.6	9
132	Novel treatment strategies for patients with nonalcoholic fatty liver disease. <i>Clinical Investigation</i> , 2011 , 1, 229-239		5
131	OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results. <i>Gut</i> , 2011 , 60, A50-A51	19.2	
130	Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). <i>Scandinavian Journal of Gastroenterology</i> , 2011 , 46, 479-84	2.4	49
129	A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. <i>Value in Health</i> , 2010 , 13, 128-31	3.3	26
128	Response to the Letter from Ms. Tamzin Furtado. <i>Value in Health</i> , 2010 , 13, 508	3.3	1
127	Clinical predictors of fibrosis in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1085-94	6.1	23
126	Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 487-97	6.1	106
125	Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 730-6	3.4	8
124	Non-alcoholic fatty liver disease after liver transplantation: a case of nurture and nature. <i>American Journal of Gastroenterology</i> , 2010 , 105, 621-3	0.7	11
123	Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. <i>Gut</i> , 2010 , 59, 1410-5	19.2	184
122	Non-invasive diagnostic tests for non-alcoholic fatty liver disease. <i>Current Molecular Medicine</i> , 2010 , 10, 166-72	2.5	23
121	Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 718-23	6.9	32
120	Manifestations of chronic hepatitis C virus infection beyond the liver. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 1017-29	6.9	121
119	Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. <i>Journal of Proteome Research</i> , 2010 , 9, 3218-24	5.6	18
118	Treatment options for nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2010 , 3, 121-37	4.7	103
117	Hepatitis C and metabolic syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2010 , 5, 209-215	4.1	
116	Emerging therapies for hepatitis C virus. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 535-44	3.7	19

115	Nutritional assessments of patients with non-alcoholic fatty liver disease. <i>Obesity Surgery</i> , 2010 , 20, 154-60	3.7	33
114	Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. <i>Obesity Surgery</i> , 2010 , 20, 640-50	3.7	40
113	Hepatic stellate cell and myofibroblast-like cell gene expression in the explanted cirrhotic livers of patients undergoing liver transplantation. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 496-504	4	4
112	Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. <i>BMC Molecular Biology</i> , 2010 , 11, 39	4.5	82
111	Markers of Insulin Resistance during HVC Treatment: A Relationship to Sustained Virologic Response. <i>FASEB Journal</i> , 2010 , 24, 659.4	0.9	
110	Treatment regimens for non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2009 , 8, S51-S59	3.1	36
109	Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. <i>Hepatology</i> , 2009 , 49, 763-74	11.2	35
108	Predictors of health-related quality of life in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 469-76	6.1	114
107	Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. <i>Liver International</i> , 2009 , 29 Suppl 2, 3-12	7.9	40
106	Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. <i>Liver International</i> , 2009 , 29, 1403-12	7.9	14
105	Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. <i>Obesity Surgery</i> , 2009 , 19, 617-24	3.7	38
104	Long-term follow-up of patients with nonalcoholic fatty liver. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 234-8	6.9	554
103	Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 1224-9, 1229.e1-2	6.9	207
102	Nonalcoholic fatty liver disease: a practical approach to evaluation and management. <i>Clinics in Liver Disease</i> , 2009 , 13, 249-66	4.6	48
101	Monoclonal and polyclonal antibodies against the HCV envelope proteins. <i>Clinics in Liver Disease</i> , 2009 , 13, 477-86	4.6	5
100	Reply:. <i>Liver International</i> , 2008 , 28, 286-287	7.9	
99	Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 2-12	6.1	114
98	A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 370-8	3.4	31

97	Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2263-71	0.7	255
96	Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2008 , 49, 608-12	13.4	473
95	Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008 , 2, 207-15	4.2	20
94	Effects of weight loss on nonalcoholic fatty liver disease. <i>Seminars in Liver Disease</i> , 2008 , 28, 427-33	7.3	58
93	Adipokines and cytokines in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 412-21	6.1	318
92	The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). <i>Quality of Life Research</i> , 2008 , 17, 575-84	3.7	39
91	A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). <i>Obesity Surgery</i> , 2008 , 18, 1430-7	3.7	228
90	Metabolic syndrome after laparoscopic bariatric surgery. <i>Obesity Surgery</i> , 2008 , 18, 1278-86	3.7	31
89	Reply to the Letter to the Editor: A Biomarker Biopsy For the Diagnosis of NASH: Promises from CK-18 Fragments by Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. <i>Obesity Surgery</i> , 2008 , 18, 1509-1510	3.7	2
88	Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. <i>Liver Transplantation</i> , 2008 , 14, 321-6	4.5	53
87	Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. <i>Cleveland Clinic Journal of Medicine</i> , 2008 , 75, 721-8	2.8	210
86	The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. <i>Clinics in Liver Disease</i> , 2007 , 11, 209-20, xi	4.6	22
85	Pathologic assessment of non-alcoholic fatty liver disease. <i>Clinics in Liver Disease</i> , 2007 , 11, 17-23, vii	4.6	53
84	The effects of HCV infection and management on health-related quality of life. <i>Hepatology</i> , 2007 , 45, 806-16	11.2	141
83	A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. <i>Hepatology</i> , 2007 , 46, 166-72	11.2	41
82	Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: the hepatitis B quality of life instrument, version 1.0. <i>Hepatology</i> , 2007 , 46, 113-21	11.2	46
81	Reply:. <i>Hepatology</i> , 2007 , 46, 1306-1307	11.2	
80	Health-related quality of life in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 815-20	6.1	79

79	Impact of non-alcoholic fatty liver disease on chronic hepatitis B. <i>Liver International</i> , 2007 , 27, 607-11	7.9	78
78	Health-related quality of life in patients with chronic hepatitis B. <i>Liver International</i> , 2007 , 27, 1119-25	7.9	62
77	Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 2531-9	4	122
76	Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. <i>Obesity Surgery</i> , 2007 , 17, 1111-8	3.7	43
75	Evaluation and management of obesity-related nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007 , 4, 432-41		74
74	Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. <i>Psychosomatics</i> , 2007 , 48, 223-9	2.6	34
73	Epidemiology and natural history of NAFLD and NASH. <i>Clinics in Liver Disease</i> , 2007 , 11, 1-16, vii	4.6	334
72	Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. <i>Expert Review of Molecular Diagnostics</i> , 2007 , 7, 195-205	3.8	14
71	Adipokines in Non-Alcoholic Fatty Liver Disease 2007 , 291-305		2
70	Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. <i>Liver Transplantation</i> , 2006 , 12, 1381-9	4.5	101
69	Depression, anemia and health-related quality of life in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006 , 44, 491-8	13.4	111
68	Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. <i>Obesity Surgery</i> , 2006 , 16, 1118-25	3.7	92
67	Non-alcoholic fatty liver disease and hepatitis C infection. <i>Minerva Gastroenterologica E Dietologica</i> , 2006 , 52, 135-43	1.6	28
66	The metabolic syndrome and nonalcoholic fatty liver disease. <i>Panminerva Medica</i> , 2006 , 48, 41-8	2	16
65	Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. <i>Clinics in Liver Disease</i> , 2005 , 9, 617-34, vi	4.6	26
64	Health-related quality of life (HRQL) in chronic liver disease. <i>Digestive and Liver Disease</i> , 2005 , 37, 819-20, 3		23
63	The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. <i>Journal of Clinical Gastroenterology</i> , 2005 , 39, S9-13	3	48
62	High rates of uninsured among HCV-positive individuals. <i>Journal of Clinical Gastroenterology</i> , 2005 , 39, 826-30	3	22

61	Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2005 , 39, S23-7	3	40
60	Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. <i>Obesity Surgery</i> , 2005 , 15, 310-5	3.7	232
59	Obesity-related differential gene expression in the visceral adipose tissue. <i>Obesity Surgery</i> , 2005 , 15, 758-65	3.7	60
58	Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. <i>Liver International</i> , 2005 , 25, 760-71	7.9	80
57	Microarray technology in the study of obesity and non-alcoholic fatty liver disease. <i>Liver International</i> , 2005 , 25, 1091-6	7.9	11
56	Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. <i>Hepatology</i> , 2005 , 41, 790-800	11.2	286
55	A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005 , 42, 665-74	11.2	172
54	MELD fails to measure quality of life in liver transplant candidates. <i>Liver Transplantation</i> , 2005 , 11, 218-235	4.5	96
53	Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 970-5	4	12
52	Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004 , 19, S253-S257	4	3
51	Nonalcoholic Steatohepatitis. <i>Current Treatment Options in Gastroenterology</i> , 2004 , 7, 423-430	2.5	2
50	Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. <i>Hepatology</i> , 2004 , 40, 1450-8	11.2	119
49	Nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 262-5	6.9	306
48	Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. <i>Human Pathology</i> , 2004 , 35, 196-9	3.7	122
47	Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2004 , 38, 705-9	3	84
46	Nonalcoholic fatty liver disease and the epidemic of obesity. <i>Cleveland Clinic Journal of Medicine</i> , 2004 , 71, 657-64	2.8	25
45	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003 , 38, 75-85	11.2	448
44	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2060-3	0.7	151

43	The impact of liver disease on health-related quality of life: a review of the literature. <i>Current Gastroenterology Reports</i> , 2002 , 4, 79-83	5	35
42	Nonalcoholic fatty liver disease: an agenda for clinical research. <i>Hepatology</i> , 2002 , 35, 746-52	11.2	175
41	Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?. <i>Gastroenterology</i> , 2002 , 123, 375-8	13.3	29
40	The utility of radiological imaging in nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2002 , 123, 745-50	13.3	1433
39	Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. <i>Liver</i> , 2001 , 21, 266-71		111
38	The role of liver biopsy in chronic hepatitis C. <i>Hepatology</i> , 2001 , 33, 196-200	11.2	153
37	Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. <i>Liver Transplantation</i> , 2001 , 7, 797-801	4.5	185
36	Health-related quality of life in chronic liver disease: the impact of type and severity of disease. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2199-205	0.7	226
35	Assessment of utilities and health-related quality of life in patients with chronic liver disease. <i>American Journal of Gastroenterology</i> , 2001 , 96, 579-83	0.7	116
34	Clinical features and natural history of nonalcoholic steatosis syndromes. <i>Seminars in Liver Disease</i> , 2001 , 21, 17-26	7.3	418
33	A pharmaco-economic appraisal of therapies for hepatitis B and C. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 205-11	4	1
32	Chronic liver disease and health-related quality of life. <i>Gastroenterology</i> , 2001 , 120, 305-7	13.3	39
31	Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. <i>American Journal of Medicine</i> , 2001 , 111, 614-21	2.4	63
30	Hepatitis C, interferon alfa, and depression. <i>Hepatology</i> , 2000 , 31, 1207-11	11.2	162
29	Impact of liver transplantation on health-related quality of life. <i>Liver Transplantation</i> , 2000 , 6, 779-83	4.5	76
28	Cholestatic liver diseases and health-related quality of life. <i>American Journal of Gastroenterology</i> , 2000 , 95, 497-502	0.7	121
27	Immunogenicity of hepatitis A vaccine in decompensated liver disease. <i>American Journal of Gastroenterology</i> , 1999 , 94, 1601-4	0.7	70
26	Nonalcoholic fatty liver disease. <i>Current Gastroenterology Reports</i> , 1999 , 1, 57-62	5	27

25	Hepatic iron and nonalcoholic fatty liver disease. <i>Hepatology</i> , 1999 , 30, 847-50	11.2	181
24	Evidence-based medicine: a method for solving clinical problems in hepatology. <i>Hepatology</i> , 1999 , 30, 829-32	11.2	11
23	Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. <i>Hepatology</i> , 1999 , 30, 1318-24	11.2	147
22	Outcome of de novo hepatitis C virus infection in heart transplant recipients. <i>Hepatology</i> , 1999 , 30, 1293-8	11.2	74
21	Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. <i>Gut</i> , 1999 , 45, 295-300	19.2	412
20	Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. <i>Gastroenterology</i> , 1999 , 116, 1413-9	13.3	2579
19	Agreement in pathologic interpretation of liver biopsy specimens in posttransplant hepatitis C infection. <i>Archives of Pathology and Laboratory Medicine</i> , 1999 , 123, 143-5	5	13
18	Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. <i>Transplantation</i> , 1999 , 67, 272-5	1.8	55
17	The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. <i>Seminars in Liver Disease</i> , 1999 , 19 Suppl 1, 95-102	7.3	10
16	Selective Digestive Decontamination and its Use in Patients with Liver Disease. <i>Disease Management and Health Outcomes</i> , 1998 , 4, 17-26		2
15	Evaluating asymptomatic patients with mildly elevated liver enzymes. <i>Cleveland Clinic Journal of Medicine</i> , 1998 , 65, 150-8	2.8	4
14	Hepatitis C update: implications of the blood transfusion "lookback". <i>Cleveland Clinic Journal of Medicine</i> , 1998 , 65, 412-5, 418-22	2.8	3
13	Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. <i>Modern Pathology</i> , 1998 , 11, 560-5	9.8	185
12	Chronic hepatitis C: a clinical overview. <i>Cleveland Clinic Journal of Medicine</i> , 1997 , 64, 259-68	2.8	9
11	Alpha-1 Antitrypsin Deficiency and the Liver140-154		
10	Acute Viral Hepatitis1-25		
9	Autoimmune Liver Disease155-173		
8	Benign and Malignant Tumors of the Liver195-214		

7	Genetic Hemochromatosis and Iron Overload	117-130	
6	Drug-Induced Liver Disease (DILI)	174-194	
5	Complications of Cirrhosis	215-234	1
4	Novel Technologies in Studying Chronic Liver Disease	256-276	
3	Chronic Hepatitis C	39-60	1
2	HIV and Viral Hepatitis	61-76	
1	Chronic Hepatitis B and D	26-38	1